19th Aug 2026 16:52
(Alliance News) - Nuformix PLC shares spiked on Wednesday after the company shared positive results from its first preclinical studies on inhaled treatments for fibrosis.
The pharmaceutical development company closed up 25% at 0.18 pence in London on Wednesday.
Nuformix said the results provide a clearer understanding of the effective dose range for inhaled NXP002, the company's lead asset and potential novel treatment for fibrosis.
By Camilla Borri, Alliance News reporter
Comments and questions to [email protected]
Copyright 2026 Alliance News Ltd. All Rights Reserved.
Related Shares:
Nuformix